BioNxt Solutions Secures European Patent for Sublingual Cladribine Platform

BioNxt Solutions Inc. has secured a Unitary European Patent for its sublingual cladribine oral thin film (ODF) platform. The patent, registered by the European Patent Office, offers centralized protection across 18 European countries, including significant markets such as Germany and France. This patent strengthens BioNxt's intellectual property with long-term protection.

The patented technology focuses on a cladribine-cyclodextrin complex within a hydrophilic polymer, aiding in the treatment of multiple sclerosis and other autoimmune disorders. The unitary patent simplifies patent protection enforcement, facilitating regional licensing and market access across Europe.

BioNxt's ODF platform significantly progressed in preclinical and clinical studies, showcasing promising bioavailability and patient compliance improvements. The company plans further human studies to compare its ODF formulation with existing products, aiming for regulatory approvals.